Uploaded to You Tube by HirshbergFoundation on Apr 26, 2011
Extensive epidemiologic data now suggest that diabetic patients who had taken metformin, especially those with greater than 5 years of use, had a significantly lower risk of developing pancreatic cancer compared with those who had not taken metformin. In contrast, diabetic patients who had taken insulin or insulin secretagogues had a significantly higher risk of pancreatic cancer compared with diabetic patients who had not taken these drugs. These population-based cohort studies raise the possibility that metformin might have a significant role in the prevention of the development of pancreatic cancer in this high risk type-2 diabetes patient group.
No comments:
Post a Comment